These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31110191)

  • 1. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.
    Uehara T; Choong CJ; Nakamori M; Hayakawa H; Nishiyama K; Kasahara Y; Baba K; Nagata T; Yokota T; Tsuda H; Obika S; Mochizuki H
    Sci Rep; 2019 May; 9(1):7567. PubMed ID: 31110191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease.
    Huang S; Li YJ; Wu JY; Hao XY; Xu WJ; Tang YC; Zhou M; Zhang JC; Luo S; Xiang DX
    Acta Biomater; 2024 Mar; 177():316-331. PubMed ID: 38244661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.
    McLean JR; Hallett PJ; Cooper O; Stanley M; Isacson O
    Mol Cell Neurosci; 2012 Feb; 49(2):230-9. PubMed ID: 22155155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Therapeutic Horizons:
    Caramiello AM; Pirota V
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
    Cole TA; Zhao H; Collier TJ; Sandoval I; Sortwell CE; Steece-Collier K; Daley BF; Booms A; Lipton J; Welch M; Berman M; Jandreski L; Graham D; Weihofen A; Celano S; Schulz E; Cole-Strauss A; Luna E; Quach D; Mohan A; Bennett CF; Swayze EE; Kordasiewicz HB; Luk KC; Paumier KL
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33682798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys.
    Alarcón-Arís D; Pavia-Collado R; Miquel-Rio L; Coppola-Segovia V; Ferrés-Coy A; Ruiz-Bronchal E; Galofré M; Paz V; Campa L; Revilla R; Montefeltro A; Kordower JH; Vila M; Artigas F; Bortolozzi A
    EBioMedicine; 2020 Sep; 59():102944. PubMed ID: 32810825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
    Chiba-Falek O; Lopez GJ; Nussbaum RL
    Mov Disord; 2006 Oct; 21(10):1703-8. PubMed ID: 16795004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
    Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
    Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
    Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
    Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32.
    Pavlou MAS; Colombo N; Fuertes-Alvarez S; Nicklas S; Cano LG; Marín MC; Goncalves J; Schwamborn JC
    Mol Neurobiol; 2017 Aug; 54(6):4257-4270. PubMed ID: 27339877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
    Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
    Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.
    Matsumoto L; Takuma H; Tamaoka A; Kurisaki H; Date H; Tsuji S; Iwata A
    PLoS One; 2010 Nov; 5(11):e15522. PubMed ID: 21124796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
    Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
    CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA.
    Zhang P; Park HJ; Zhang J; Junn E; Andrews RJ; Velagapudi SP; Abegg D; Vishnu K; Costales MG; Childs-Disney JL; Adibekian A; Moss WN; Mouradian MM; Disney MD
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1457-1467. PubMed ID: 31900363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
    Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
    PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA gene.
    Pirota V; Rey F; Esposito L; Fantini V; Pandini C; Maghraby E; Di Gerlando R; Doria F; Mella M; Pansarasa O; Gandellini P; Freccero M; Carelli S; Cereda C
    Int J Biol Macromol; 2024 Oct; 277(Pt 4):134417. PubMed ID: 39098688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.